ClinicalTrials.gg
RecruitingNCT06994377EIRENEUpdated Jun 17, 2026

Emotional Distress in Patients With Metastatic Breast Cancer in First Line of Therapy

An observational study in Metastatic Breast Cancer, sponsored by European Institute of Oncology. Recruiting at 37 sites in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-17.

Sponsored by European Institute of Oncology · Observational

How we know · 3 judgments

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,000
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 64 studies in Breast Neoplasms by European Institute of Oncology — 40 open to participants now, 48 under way, 2 of them phase 3. Breast Neoplasms · European Institute of Oncology.

Planned enrollment
2nd of 27
1,000 · median 200
Started
2025
with 7 others
Observational
27 of 64
21 open now
Primary completion
2029-06
later than 43 of 47 live
Registered
57th of 64
by date

Among the 64 studies in Breast Neoplasms by European Institute of Oncology, this one is the 2nd largest by planned enrollment of the 27 observational ones that give a count, is one of 8 that started in 2025, is one of 27 observational ones, reaches primary completion later than 43 of the 47 other live ones, and was the 57th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

40 of the 64 studies in Breast Neoplasms by European Institute of Oncology are open now, in 1 country. Recruiting first, the newest first:

34 more — sign in →

By country, each count listing its studies:

All 40 open studies →

Where they have run

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 64 studies in Breast Neoplasms by European Institute of Oncology, or all of them as a file.
02

Study summary

Few data about the impact of emotional distress (ED) on treatment efficacy in patients with metastatic breast cancer (mBC) are available.

Aim of this study is to assess the outcomes of patients with mBC receiving first-line treatment according to the presence of baseline ED.

Read the detailed description

Metastatic breast cancer (mBC) is the most incident and prevalent cancer in the world and, according to a recent meta-analysis, 50% of patients with BC report emotional distress (ED).

In patients with cancer, ED negatively impacts treatment adherence, ability to self-manage the physical and emotional consequences of cancer symptoms and treatment-related adverse events, and overall quality of life. ED has been shown to directly affect treatment outcomes in patients with breast cancer, with studies demonstrating that psychological well-being plays a critical role in therapeutic success.

Furthermore, recent studies showed that baseline ED is associated with a lower efficacy of immunotherapy in patients with non-small cell lung cancer (NSCLC) or melanoma.

Few data about the impact of ED on treatment efficacy in patients with mBC are available. In the first line setting patients receive endocrine therapy, chemotherapy, immunotherapy and/or targeted therapy according to the disease subtype. These agents display different mechanisms of action, which involve the immune system at different levels. However, the role of ED on the efficacy of these treatments according to the BC subtype is unknown.

Aim of this study is to assess the outcomes of patients with mBC receiving first-line treatment according to the presence of baseline ED.

03

Conditions studied

  • Metastatic Breast Cancer

Browse trials for

Keywords

  • Metastatic Breast Cancer
  • Emotional Distress
  • First Line Therapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with mBC eligible for standard 1st line treatment

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age over 18 years
  • Confirmed histological diagnosis of breast cancer
  • No prior treatment for advanced/ cancer
  • Indication to receive therapy as per standard clinical practice based on the disease subtype:

    1. cohort A (HR-/-, +): pembrolizumab or atezolizumab + chemotherapy
    2. cohort B (HR-/HER2-, PD-L1-): chemotherapy
    3. cohort C (HR+/HER2-): CDK4/6 inhibitor + endocrine therapy
    4. cohort D (HER2+): chemotherapy + trastuzumab and pertuzumab
  • Presence of according to (RECIST) v.1.1 and/or Positron Emission Tomography Response Criteria in Solid Tumors (PERCIST) criteria
  • Able to provide full for the study

Exclusion criteria

Exclusion Criteria:

  • Pre-existing severe psychiatric disorders or other conditions that could impair the ability to provide
  • Inability to complete questionnaires
  • Presence of another in the previous 3 years
  • Symptomatic
  • Ongoing treatment with antidepressant and/or anxiolytic drugs
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • Cohort A (HR-/HER2-, PD-L1+)

    Triple-negative Programmed Cell Death Ligand 1 (PD-L1)+ mBC patients receiving chemotherapy with immune checkpoint inhibitors (ICIs)

    Behavioral: ED and quality of life assessment

  • Cohort B (HR-/HER2-, PD-L1-)

    Triple-negative PD-L1- mBC patients receiving chemotherapy

    Behavioral: ED and quality of life assessment

  • Cohort C (HR+/HER2-)

    HR+/HER2- mBC patients receiving Cyclin-Dependent Kinase 4/6 (CDK4/6) inhibitor + endocrine therapy

    Behavioral: ED and quality of life assessment

  • Cohort D (HER2+)

    HER2+ mBC patients receiving chemotherapy + trastuzumab and pertuzumab

    Behavioral: ED and quality of life assessment

Interventions

  • BehavioralED and quality of life assessment

    Patients will undergo ED and quality of life assessments through specific questionnaires completion

This study also gives TrastuzumabStudies of TrastuzumabTrastuzumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record., PertuzumabStudies of PertuzumabPertuzumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Progression-free survival (PFS), according to the presence of ED at T0, in cohort A

    Time from T0 (Cycle 1 Day 1) to disease progression or death

    Time frame: 2 years

Secondary outcomes

  1. Progression-free survival (PFS), according to the presence of ED at T0, in cohort B, C and D

    Time from T0 (Cycle 1 Day 1) to disease progression or death

    Time frame: 2 years

  2. Progression-free survival (PFS), according to the presence of ED at T1 (Cycle 3 Day 1)

    Time from T0 (Cycle 1 Day 1) to disease progression or death

    Time frame: 2 years

  3. Objective response rate (ORR), according to the presence of ED at T0 and T1

    Number of partial response or complete response achieved

    Time frame: 2 years

  4. Quality of life evaluation

    Completion of European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) EORTC-QLQ-C30 (minimum value: 1, maximum value: 4 - higher scores mean a greater agreement with the statement)

    Time frame: 3 months

  5. Fear of cancer progression evaluation

    Completion of Fear of Progression Questionnaire (FoP Q) (minimum value: 1, maximum value: 5 - higher total score reflects a higher level of fear of disease progression)

    Time frame: 3 months

07

Study locations

8 of 37 sites recruiting
  • Ospedali Riuniti di Ancona
    Ancona, Italy
    Not yet recruiting
    • Rossana Berardi · Contact
  • CRO (Centro di Riferimento Oncologico)
    Aviano, Italy
    Not yet recruiting
    • Fabio Puglisi, MD · Contact
  • Azienda Usl Toscana centro - Ospedale Santa Maria Annunziata
    Bagno a Ripoli, Italy
    Recruiting
    • Carlotta Bacci, MD · Contact
  • IRCCS Istituto Tumori Giovanni Paolo II
    Bari, Italy
    Not yet recruiting
    • Nicola Silvestris, MD · Contact
  • ASST Papa Giovanni XXIII
    Bergamo, Italy
    Not yet recruiting
    • Alberto Zambelli, MD · Contact
  • ASST Spedali Civili
    Brescia, Italy
    Not yet recruiting
    • Rebecca Pedersini, MD · Contact
  • Ospedale A. Perrino
    Brindisi, Italy
    Not yet recruiting
    • Saverio Cinieri, MD · Contact
  • ASST della Valle Olona
    Busto Arsizio, Italy
    Not yet recruiting
    • Maria Marconi, MD · Contact
  • Ospedale Valduce
    Como, Italy
    Not yet recruiting
    • Giovanni Scognamiglio, MD · Contact
  • Ospedale Careggi
    Florence, Italy
    Not yet recruiting
    • Icro Meattini, MD · Contact
  • Ospedale Policlinico San Martino
    Genova, Italy
    Not yet recruiting
    • Lucia Del Mastro, MD · Contact
  • AOU Gaetano Martino di Messina
    Messina, Italy
    Recruiting
    • Massimilano Berretta, MD · Contact
  • European Institute of Oncology
    Milan, 20141, Italy
    Recruiting
    • Gabriella Pravettoni, MD · Contact
  • ASST Fatebenefratelli Sacco
    Milan, Italy
    Not yet recruiting
    • Nicla La Verde, MD · Contact
  • Fondazione IRCCS Istituto Nazionale dei Tumori
    Milan, Italy
    Not yet recruiting
    • Claudio Vernieri, MD · Contact
  • IRCCS Ospedale San Raffaele
    Milan, Italy
    Not yet recruiting
    • Giulia Viale, MD · Contact
  • Ospedale Niguarda
    Milan, Italy
    Not yet recruiting
    • Salvatore Siena, MD · Contact
  • Ospedale San Giuseppe MultiMedica
    Milan, Italy
    Not yet recruiting
    • Pier Francesco Ferrucci, MD · Contact
  • Policlinico di Milano
    Milan, Italy
    Not yet recruiting
    • Ornella Garrone, MD · Contact
  • Azienda Ospedaliero-Universitaria di Modena
    Modena, Italy
    Not yet recruiting
    • Angela Toss, MD · Contact
  • Azienda Ospedaliera Universitaria Federico II
    Naples, Italy
    Not yet recruiting
    • Roberto Bianco, MD · Contact
  • Istituto Nazionale Tumori IRCCS Fondazione G. Pascale
    Naples, Italy
    Not yet recruiting
    • Michelino De Laurentiis, MD · Contact
  • Ospedale Maggiore di Novara
    Novara, Italy
    Not yet recruiting
    • Alessandra Gennari, MD · Contact
  • Policlinico Universitario Paolo Giaccone
    Palermo, Italy
    Not yet recruiting
    • Antonio Russo, MD · Contact
  • Policlinico San Matteo
    Pavia, Italy
    Not yet recruiting
    • Paolo Pedrazzoli, MD · Contact
  • Azienda Ospedaliero Universitaria Pisana
    Pisa, Italy
    Not yet recruiting
    • Chiara Cremolini, MD · Contact
  • Azienda Ospedaliero Universitaria Pisana
    Pisa, Italy
    Recruiting
    • Carmelo Bengala, MD · Contact
  • Azienda Usl Toscana centro - Ospedale di Prato Santo Stefano
    Prato, Italy
    Recruiting
    • Laura Biganzoli, MD · Contact
  • Ospedale Infermi
    Rimini, Italy
    Not yet recruiting
    • Lorenzo Gianni, MD · Contact
  • Policlinico Universitario Campus Bio-Medico
    Roma, Italy
    Not yet recruiting
    • Francesco Pantano, MD · Contact
  • Policlinico Umberto I
    Rome, Italy
    Not yet recruiting
    • Andrea Botticelli, MD · Contact
  • Policlinico Universitario Agostino Gemelli IRCCS
    Rome, Italy
    Recruiting
    • Alessandra Fabi, MD · Contact
  • Azienda Ospedaliero Universitaria di Sassari
    Sassari, Italy
    Recruiting
    • Valeria Sanna, MD · Contact
  • ASL CN2 - Ospedale Michele e Pietro Ferrero
    Verduno, Italy
    Recruiting
    • Veronica Prati, MD · Contact
  • Azienda Ospedaliera Universitaria Integrata Verona
    Verona, Italy
    Not yet recruiting
    • Elena Fiorio, MD · Contact
  • Ospedale Sacro Cuore Don Calabria - Negrar
    Verona, Italy
    Not yet recruiting
    • Stefania Gori, MD · Contact
  • ASST Brianza
    Vimercate, Italy
    Not yet recruiting
    • Paola Tagliabue, MD · Contact
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Jun 2029, 48 months after the start.

Of 1,193 non-industry observational studies under Breast Neoplasms, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 139. This study's planned 48 months is below that.

Counting every sponsor, half of 1,382 studies reached it within 55 months; a quarter within 25 and three quarters within 126.

How these figures are worked out, and which studies are left out of them.

Registered
May 20, 2025
First posted
May 29, 2025
StartActual
Jun 25, 2025
Primary completionEst.
Jun 2029
CompletionEst.
Jun 2029
Last update
Jun 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06994377
Responsible party
Sponsor
First posted
May 29, 2025
Start date
Jun 25, 2025
Primary completion
Jun 2029 (estimated)
Completion
Jun 2029 (estimated)
Last update
Jun 17, 2026

Study contacts

Gabriella Pravettoni, MD, PhD
Contact
gabriella.pravettoni@ieo.it
+39 0257489731
Mara Negri
Contact
mara.negri@ieo.it
+39 0257489536
Gabriella Pravettoni, MD, PhD
principal investigator · European Istitute of Oncology

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion